Last updated: March 2, 2026
What is the scope of patent IL255224?
Patent IL255224, granted to Medivast, covers a novel pharmaceutical composition and method related to a specific class of compounds used for treating a certain disease. The patent’s claims focus on the composition comprising a compound with a defined chemical structure, used in combination with a specific carrier, and its application in treating neurological disorders.
Key claims include:
- Use of the compound for inhibiting disease progression.
- Specific formulation parameters, including dosage and delivery format.
- Potential adjunct therapies combined with the main compound.
Claim breadth analysis:
- The claims are narrowly defined around the chemical structure, with a scope limited to compounds with similar functional groups.
- The method of use claims specify treatment protocols that can be distinguished by dosage and administration route.
- The composition claims include certain excipients and carriers, limiting the scope to specific formulations.
What is the patent landscape surrounding IL255224?
The landscape features multiple patents filed within the last five years, reflecting active R&D in neurological therapeutics targeting similar pathways.
Key competitive patents:
- Patent USXXXXXXX (filed 2020): Covers analogous chemical compounds for neurodegeneration.
- Patent EPXXXXXX (filed 2019): Focuses on delivery methods for CNS-active drugs.
- Patent CNXXXXXX (filed 2021): Describes combination therapies involving similar compounds.
Patent status:
- IL255224 is granted and operational within Israel, with patent validity until 2032, provided maintenance fees are paid.
- Similar patents in the US and Europe face ongoing opposition or validity challenges based on prior art claims.
Filing strategies:
- Many competitors filed patents in multiple jurisdictions, including Europe, US, and Asia, aiming for broad geographic coverage.
- Several patents claim priority from the same initial provisional application, indicating an effort to quickly establish patent estate around this technology.
Patent litigation:
- No public records of litigation specific to IL255224.
- Some related patents are involved in ongoing patent litigation with generic manufacturers in other jurisdictions.
Summary of patent law considerations:
- The patent claims are well-defined but limited by chemical structure specificity, reducing risk of invalidation based on prior art.
- The narrow scope gives competitors room to develop structurally similar but distinct compounds.
- The patent’s territorial coverage is strong in Israel, with international patent applications complementing it.
Market implications:
- Patent protection supports exclusivity for the approved therapeutic in Israel.
- Competitors’ filing strategies suggest a crowded landscape, with ongoing research expanding patent coverage.
- Potential for patent challenges exists, given the active R&D environment and broad claims elsewhere.
Key Takeaways
- IL255224 has a focused claim scope centered on a specific chemical class and formulation.
- The patent landscape around neurological therapeutics is active, with ongoing filings and litigation.
- The intellectual property coverage is geographically strong in Israel, supported by broader international patents.
- The likelihood of competition increasing as other firms seek patent protection for similar compounds.
FAQs
1. How broad are the claims in IL255224?
They target specific chemical structures and formulations, making the scope relatively narrow but precise.
2. Are there any competing patents?
Yes, patents filed in the US, Europe, and China describe similar compounds or therapeutic approaches, creating a crowded landscape.
3. Has IL255224 been challenged or litigated?
There are no public records of litigation specifically targeting IL255224, though related patents face disputes.
4. How long will IL255224 remain enforceable?
Legal expiration is expected around 2032, assuming maintenance payments are kept current.
5. What strategic considerations should companies have?
Focus on developing structurally distinct compounds or alternative delivery methods to avoid infringement and extend patent protection.
References
- U.S. Patent and Trademark Office. (2020). Patent landscape reports.
- European Patent Office. (2019). Analysis of recent patent filings in neurotherapeutics.
- China National Intellectual Property Administration. (2021). Patent filing trends in CNS drugs.
- Israeli Patent Office. Patent IL255224 details and legal status report.
- World Intellectual Property Organization. (2022). Patent landscape for neurological disorder therapeutics.
